登录 | 注册    关注公众号  
搜索

LILRB2信息

英文名称:Leukocyte immunoglobulin-like receptor subfamily B member 2
中文名称:白细胞免疫球蛋白样受体亚家族B成员2
靶点别称:Leukocyte immunoglobulin-like receptor 2,CD85 antigen-like family member D,Immunoglobulin-like transcript 4,ILT-4,Monocyte/macrophage immunoglobulin-like receptor 10,MIR-10,CD_antigen: CD85d,LILRB2,Leukocyte Immunoglobulin Like Receptor B2,Leucocyte Ig-Like Receptor B2,MIR10,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 2,Ig-Like Transcript 4,Myeloid Inhibitory Receptor 10,CD85d Antigen,ILT4,LIR2,CD85d,LIR-2,LIRB2
上市药物数量:0
临床药物数量:4
最高研发阶段:临床二期

LILRB2 分子别名

LILRB2,ILT4,LIR2,MIR10,CD85d

LILRB2 分子背景

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB2 前沿进展

LILRB2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
NGM-707 NGM-707 Merck & Co, Ngm Biopharmaceuticals 详情
IO-108 IO-108 临床一期 以明生物医药科技(杭州)有限公司 实体瘤 详情
JTX-8064 JTX-8064 Jounce Therapeutics 详情
MK-4830 MK-4830 临床二期 默沙东 肾细胞癌, 小细胞肺癌, 卵巢上皮癌, 子宫浆液性癌, 食管鳞状细胞癌, 非小细胞肺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定